The European Medicines Agency is considering revisions to its guideline on the evaluation of new anti-cancer agents in response to a growing number of new therapies, including vaccines and immunotherapies, that have entered clinical trials. ---Subscribe to MedNous to access this article--- Regulation & Policy
